Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: Promising ligands for anti-androgen withdrawal syndrome

Journal of Medicinal Chemistry

Volumn 53, Issue 13, 2010, Pages 4917-4926

  Goto, Tokuhito ^a   Ohta, Kiminori ^a   Fujii, Shinya ^b   Ohta, Shigeru ^c   Endo, Yasuyuki ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (12 HYDROXYMETHYL 1,12 DICARBA CLOSO DODECABORANE 1 YL)BENZONITRILE; ANDROGEN RECEPTOR; ANTIANDROGEN; BA 341; BENZONITRILE; BICALUTAMIDE; CARBORANE DERIVATIVE; HYDROXYFLUTAMIDE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRAIN SC 3; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; MALE; PHARMACOPHORE; PROSTATE CANCER; TRANSACTIVATION; WITHDRAWAL SYNDROME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BORANES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 77954337049     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100316f     Document Type: Article

References (72)

1. Mooradian, A. D.; Morley, J. E.; Korenman, S. G. Biological actions of androgens Endocr. Rev. 1987, 8, 1-28
2. Bagatell, C. J.; Bremner, W. J. Androgens in men-uses and abuses N. Engl. J. Med. 1996, 334, 707-714
3. Kaufman, J. M.; Vermeulen, A. The decline of androgen levels in elderly men and its clinical and therapeutic implications Endocr. Rev. 2005, 26, 833-876
4. Evans, R. M. The steroid and thyroid hormone receptor superfamily Science 1988, 240, 889-894
5. MacLean, H. E.; Warne, G. L.; Zajac, J. D. Localization of functional domains in the androgen receptor J. Steroid Biochem. Mol. Biol. 1997, 62, 233-242
6. McEwan, I. J. Gene regulation through chromatin remodeling by members of the nuclear receptor superfamily Biochem. Soc. Trans. 2000, 28, 369-373
7. Taplin, M.-E. Androgen receptor: role and novel therapeutic prospects in prostate cancer Expert. Rev. Anticancer Ther. 2008, 8, 1495-1508
8. Chengalvala, M.; Oh, T.; Roy, A. K. Selective androgen receptor modulators Expert Opin. Ther. Pat. 2003, 13, 59-66
9. Gao, W.; Bohl, C. E.; Dalton, J. T. Chemistry and structural biology of androgen receptor Chem. Rev. 2005, 105, 3352-3370
10. Chen, J.; Kim, J.; Dalton, J. T. Discovery and therapeutic promise selective androgen receptor modulators Mol. Invest. 2005, 5, 173-188
11. Neri, R. O.; Peets, E. A. Biological aspects of antiandrogens J. Steroid Biochem. 1975, 6, 815-819
12. Koch, H. Flutamide-a new non-steroidal anti-androgen Drugs Today 1984, 20, 561-574
13. Neri, R. Pharmacology and pharmacokinetics of flutamide Urology 1989, 34, 19-21
14. Wakeling, A. E.; Furr, B. J.; Glen, A. T.; Hughes, L. R. Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens J. Steroid Biochem. 1981, 15, 355-359
15. Yeh, S.; Miyamoto, H.; Chang, C. Hydroxyflutamide may not always be a pure antiandrogen Lancet 1997, 349, 852-853
16. Bohl, C. E.; Miller, D. D.; Chen, J.; Bell, C. E.; Dalton, J. T. Structural basis for accommodation of nonsteroid ligands in the androgen receptor J. Biol. Chem. 2005, 280, 37747-37754
17. Tucker, H.; Chesterson, G. J. Resolution of the nonsteroidal antiandrogen 4′-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3′- (trifluoromethyl)-propionanilide and the determination of the absolute configuration of the active enantiomer J. Med. Chem. 1988, 31, 885-887
18. Fradet, Y. Bicalutamide (Casodex) in the treatment of prostate cancer Expert Rev. Anticancer Ther. 2004, 4, 37-48
19. Kolvenbag, G. J.; Blackledge, G. R.; Gotting-Smith, K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development Prostate 1998, 34, 61-72
20. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 6201-6206
21. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An, Y.; Wu, G. Y.; Scheffler, J. E.; Salvati, M. E.; Krystek, S. R., Jr.; Weinmann, R.; Einspahr, H. M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4904-4909
22. De Jésus-Tran, K. P.; Cõté, P.-L.; Cantin, L.; Blanchet, J.; Labrie, F.; Breton, R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affnity Protein Sci. 2006, 15, 987-999
23. Boccardo, F. Hormone therapy of prostate cancer: Is there a role for antiandrogen monotherapy? Crit. Rev. Oncol. Hematol. 2000, 35, 121-132
24. Suzuki, H.; Kamiya, N.; Imamoto, T.; Kawamura, K.; Yano, M.; Takano, M.; Utsumi, T.; Naya, Y.; Ichikawa, T. Current topics and perspectives relating to hormone therapy for prostate cancer Int. J. Clin. Oncol. 2008, 13, 401-410
25. Scher, H. I.; Steineck, G.; Kelly, W. K. Hormone-refractory (D3) prostate cancer: refining the concept Urology 1995, 46, 142-148
26. Taplin, M. E.; Rajeshkumar, B.; Halabi, S.; Werner, C. P.; Woda, B. A.; Picus, J.; Stadler, W.; Hayes, D. F.; Kantoff, P. W.; Vogelzang, N. J.; Small, E. J. Androgen receptor mutation in androgen-independent prostate cancer: cancer and leukemia group B study 9663 J. Clin. Oncol. 2003, 21, 2673-2678
27. Miyamoto, H.; Rahman, M. M.; Chang, C. Molecular basis for the antiandrogen withdrawal syndrome J. Cell. Biochem. 2003, 91, 3-12
28. Veldscholte, J.; Berrevoets, C. A.; Brinkmann, A. O.; Grootegoed, J. A.; Mulder, E. Anti-androgens and the mutated androgen receptor LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation Biochemistry 1992, 31, 2393-2399
29. Fenton, M. A.; Shuster, T. D.; Fertig, A. M.; Taplin, M. E.; Kolvenbag, G.; Bubley, G. J.; Balk, S. P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer Clin. Cancer Res. 1997, 3, 1383-1388
30. Zhao, X. Y.; Malloy, P. J.; Krishnan, A. V.; Swami, S.; Navone, N. M.; Peehl, D. M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat. Med. 2000, 6, 703-706
31. Taplin, M. E.; Bubley, G. J.; Ko, Y. J.; Small, E. J.; Upton, M.; Rajeshkumar, B.; Balk, S. P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res. 1999, 59, 2511-2515
32. Suzuki, H.; Akakura, K.; Komiya, A.; Aida, S.; Akimoto, S.; Shimazaki, J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome Prostate 1996, 29, 153-158
33. Zhou, J.; Liu, B.; Geng, G.; Wu, J. H. Study of the impact of the T877A mutation on ligand induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens Proteins 2010, 78, 623-637
34. Hara, T.; Miyazaki, J.; Araki, H.; Yamaoka, M.; Kanzaki, N.; Kusaka, M.; Miyamoto, M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res. 2003, 63, 149-153
35. Yoshida, T.; Kinoshita, H.; Segawa, T.; Nakamura, E.; Inoue, T.; Shimizu, Y.; Kamoto, T.; Ogawa, T. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patients Cancer Res. 2005, 65, 9611-9616
36. 12 and their derivatives Chem. Rev. 1992, 92, 209-223
37. Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Rong, F.-G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. The chemistry of neutron capture therapy Chem. Rev. 1998, 98, 1515-1562
38. Valliant, J. F.; Guenther, K. J.; King, A. S.; Morel, P.; Schaffer, P.; Sogbein, O. O.; Stephenson, K. A. The medicinal chemistry of carboranes Coord. Chem. Rev. 2002, 232, 173-230
39. Armstrong, A. F.; Valliant, J. F. The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy Dalton Trans. 2007, 4240-4251
40. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Yamaguchi, M.; Fukasawa, H.; Shudo, K. Potent estrogenic agonists bearing dicarba- closo -dodecaborane as a hydrophobic pharmacophore J. Med. Chem. 1999, 42, 1501-1504
41. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; Inada, M.; Kubo, A.; Itai, A. Potent agonists based on carborane as a hydrophobic skeletal structure: a new medicinal application of boron clusters Chem. Biol. 2001, 8, 341-355
42. Endo, Y.; Yoshimi, T.; Ohta, K.; Suzuki, T.; Ohta, S. Potent estrogen receptor ligands based on bisphenols with a globular hydrophobic core J. Med. Chem. 2005, 48, 3941-3944
43. Hirata, M.; Inada, M.; Matsumoto, C.; Takita, M.; Ogawa, T.; Endo, Y.; Miyaura, C. A novel carborane analogue, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone Biochem. Biophys. Res. Commun. 2009, 380, 218-222
44. Ohta, K.; Ogawa, T.; Suzuki, T.; Ohta, S.; Endo, Y. Novel estrogen receptor (ER) modulators: carbamate and thiocarbamate derivatives with m -carborane bisphenol structure Bioorg. Med. Chem. 2009, 17, 7958-7963
45. Iijima, T.; Endo, Y.; Tsuji, M.; Kawachi, E.; Kagechika, H.; Shudo, K. Dicarba- closo -dodecaboranes as a pharmacophore. Retinoidal antagonists and potential agonists Chem. Pharm. Bull. 1999, 47, 398-404
46. Endo, Y.; Yaguchi, K.; Kawachi, E.; Kagechika, H. Polymethylcarborane as a novel bioactive moiety: derivatives with potent retinoid antagonistic activity Bioorg. Med. Chem. Lett. 2000, 10, 1733-1736
47. Endo, Y.; Iijima, T.; Yaguchi, K.; Kawachi, E.; Inoue, N.; Kagechika, H.; Kubo, K.; Itai, A. Structure-activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei Bioorg. Med. Chem. Lett. 2001, 11, 1307-1311
48. Ohta, K.; Iijima, T.; Kawachi, E.; Kagechika, H.; Endo, Y. Novel retinoid X receptor (RXR) antagonists having a dicarba- closo -dodecaborane as a hydrophobic moiety Bioorg. Med. Chem. Lett. 2004, 14, 5913-5918
49. Calléja, C.; Messaddeq, N.; Chapellier, B.; Yang, H.; Krezel, W.; Li, M.; Metzger, D.; Mascrez, B.; Ohta, K.; Kagechika, H.; Endo, Y.; Mark, M.; Ghyselinck, N. B.; Chambon, P. Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes Gene Dev. 2006, 20, 1525-1538
50. Fujii, S.; Goto, T.; Ohta, K.; Hashimoto, Y.; Suzuki, T.; Ohta, S.; Endo, Y. Potent androgen antagonists based on carborane as a hydrophobic core structure J. Med. Chem. 2005, 48, 4654-4662 (Pubitemid 40993424)
51. Fujii, S.; Hashimoto, Y.; Suzuki, T.; Ohta, S.; Endo, Y. A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton Bioorg. Med. Chem. Lett. 2005, 15, 227-230
52. Goto, T.; Ohta, K.; Suzuki, T.; Ohta, S.; Endo, Y. Design and synthesis of novel androgen receptor antagonists with sterically bulky icosahedral carborane Bioorg. Med. Chem. 2005, 13, 6414-6424
53. Ohta, K.; Goto, T.; Fujii, S.; Suzuki, T.; Ohta, S.; Endo, Y. Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring Bioorg. Med. Chem. 2008, 16, 8022-8028
54. Fujii, S.; Ohta, K.; Goto, T.; Kagechika, H.; Endo, Y. Acidic heterocycles as novel hydrophilic pharmacophore of androgen receptor ligands with a carborane core structure Bioorg. Med. Chem. 2009, 17, 344-350
55. Dess, D. B.; Martin, J. C. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones J. Org. Chem. 1983, 48, 4155-4156
56. Dess, D. B.; Martin, J. C. A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species J. Am. Chem. Soc. 1991, 113, 7277-7287
57. Corey, E. J.; Chaykovsky, M. Dimethylsulfonium methylide, a reagent for selective oxirane synthesis from aldehydes and ketones J. Am. Chem. Soc. 1962, 84, 3782-3783
58. Corey, E. J.; Chaykovsky, M. Dimethyloxosulfonium methylide and dimethylsulfonium methylide. Formation and application to organic synthesis J. Am. Chem. Soc. 1965, 87, 1353-1364
59. Aggarwal, V. K.; Ali, A.; Coogan, M. P. A novel procedure for the synthesis of epoxides: Application of Simmons-Smith reagents toward epoxidation J. Org. Chem. 1997, 62, 8628-8629
60. Aggarwal, V. K.; Coogan, M. P.; Stenson, R. A.; Jones, R. V. H.; Fieldhouse, R.; Blacker, J. Developments in the Simmons-Smith-mediated epoxidation reaction Eur. J. Org. Chem. 2002, 319-326
61. Ishioka, T.; Kubo, A.; Koiso, Y.; Nagasawa, K.; Itai, A.; Hashimoto, Y. Novel non-steroidal/non-anilide type androgen antagonists with an isoxazolone moiety Bioorg. Med. Chem. 2002, 10, 1555-1566
62. Kitamura, S.; Suzuki, T.; Ohta, S.; Fujimoto, N. Antiandrogenic activity and metabolism of the organophosphorus pesticide fenthion and related compounds Environ. Health Perspect. 2003, 111, 503-508
63. Hiraoka, D.; Nakamura, N.; Nishizawa, Y.; Uchida, N.; Noguchi, S.; Matsumoto, K.; Sato, B. Inhibitory and stimulatory effects of glucocorticoid on androgen-induced growth of murine Shionogi carcinoma 115 in vivo and in cell culture Cancer Res. 1987, 47, 6560-6564 (Pubitemid 18019655)
64. Kasayama, S.; Saito, H.; Kouhara, H.; Sumitani, S.; Sato, B. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells J. Cell. Physiol. 1993, 154, 254-261
65. Culig, Z.; Hobisch, A.; Cronauer, M. V.; Cato, A. C. B.; Hittmair, A.; Radmayr, C.; Eberle, J.; Bartsch, G.; Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone Mol. Endocrinol. 1993, 7, 1541-1550
66. Taplin, M. E.; Bubley, G. J.; Shuster, T. D.; Frantz, M. E.; Spooner, A. E.; Ogata, G. K.; Keer, H. N.; Balk, S. P. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer N. Engl. J. Med. 1995, 332, 1393-1398
67. Marcelli, M.; Ittmann, M.; Mariani, S.; Sutherland, R.; Nigam, R.; Murthy, L.; Zhao, Y.; DiConcini, D.; Puxeddu, E.; Esen, A.; Eastham, J.; Weigel, N. L.; Lamb, D. J. Androgen receptor mutations in prostate cancer Cancer Res. 2000, 90, 944-949
68. Yin, D.; Gao, W.; Kearbey, J. D.; Xu, H.; Chung, K.; He, Y.; Marhefka, C. A.; Veverka, K. A.; Miller, D. D.; Dalton, J. T. Pharmacodynamics of selective androgen receptor modulators J. Pharmacol. Exp. Ther. 2003, 304, 1334-1340
69. Marhefka, C. A.; Gao, W.; Chung, K.; Kim, J.; He, Y.; Yin, D.; Bohl, C.; Dalton, J. T.; Miller, D. D. Design, synthesis and biological characterization of metabolically stable selective androgen receptor modulators J. Med. Chem. 2004, 47, 993-998
70. Kearbey, J. D.; Gao, W.; Narayanan, R.; Fisher, S. J.; Wu, D.; Miller, D. D.; Dalton, J. T. Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats Pharm. Res. 2007, 24, 328-335
71. Zhi, L.; Martinborough, E. Annu. Rep. Med. Chem. 2001, 36, 169-180
72. Brown, T. R. Nonsteroidal selective androgen receptor modulators (SARMs): designer androgens with flexible structures provide clinical promise Endocrinology 2004, 145, 5417-5419